<DOC>
	<DOC>NCT00977561</DOC>
	<brief_summary>This study will summarize the safety of patients receiving figitumumab combined with etoposide and cisplatin (or carboplatin) vs. patients receiving etoposide and cisplatin (or carboplatin) alone as first line treatment for extensive stage disease Small Cell Lung Cancer.</brief_summary>
	<brief_title>A Study Of Cisplatin (Or Carboplatin) And Etoposide With Or Without Figitumumab (CP-751,871) In Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>The study prematurely discontinued on January 26, 2011 due to slow enrollment. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Histologically confirmed diagnosis of extensive stage disease Small Cell Lung Cancer (SCLC), with tumor biopsy sample required. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Total IGF1 &gt; or = 120 ng/ml Any prior systemic therapy for Small Cell Lung Cancer (SCLC) HbA1c &gt; or = 5.7%</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Extensive stage disease</keyword>
	<keyword>SCLC</keyword>
	<keyword>IGF-1R inhibitor</keyword>
</DOC>